Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications

BACKGROUND: Cardiovascular disease (CVD) remains the most prevalent cause of morbidity and mortality in patients with type 2 diabetes (T2D) and is a primary driver for health care costs associated with diabetes management. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptid...

Descripción completa

Detalles Bibliográficos
Autores principales: Pineda, Elmor D., Liao, I-Chia, Godley, Paul J., Michel, Jeffrey B., Rascati, Karen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391160/
https://www.ncbi.nlm.nih.gov/pubmed/32347181
http://dx.doi.org/10.18553/jmcp.2020.26.5.610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391160/
https://www.ncbi.nlm.nih.gov/pubmed/32347181
http://dx.doi.org/10.18553/jmcp.2020.26.5.610

Ejemplares similares